April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Sanglifehrin A Promotes Allograft Survival in Rat Keratoplasty
Author Affiliations & Notes
  • Johannes Schwartzkopff
    University Eye Hospital Freiburg,
    University of Freiburg, Freiburg, Germany
  • Leslie Y. Olivares Valdez
    University Eye Hospital Freiburg,
    University of Freiburg, Freiburg, Germany
  • Laura Bredow
    University Eye Hospital Freiburg,
    University of Freiburg, Freiburg, Germany
  • Armin Buchwald
    Department of Clinical Chemistry,
    University of Freiburg, Freiburg, Germany
  • Daniel Böhringer
    University Eye Hospital Freiburg,
    University of Freiburg, Freiburg, Germany
  • Thomas Reinhard
    University Eye Hospital Freiburg,
    University of Freiburg, Freiburg, Germany
  • Footnotes
    Commercial Relationships  Johannes Schwartzkopff, None; Leslie Y. Olivares Valdez, None; Laura Bredow, None; Armin Buchwald, None; Daniel Böhringer, None; Thomas Reinhard, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1159. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johannes Schwartzkopff, Leslie Y. Olivares Valdez, Laura Bredow, Armin Buchwald, Daniel Böhringer, Thomas Reinhard; Sanglifehrin A Promotes Allograft Survival in Rat Keratoplasty. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1159.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Immunosuppressive strategies e.g. Cyclosporine A (CsA) promote corneal graft survival by inhibiting T cells. As soon as treatment is stopped, rejection occurs mainly because T cells are still activated by dendritic cells (DC). It is of major interest to develop strategies to selectively block DC before the initial sensitization process comes up. Therefore, the selective blockade of DC by Sanfglifehrin A (SFA) was analyzed.

Methods: : Penetrating keratoplasty was performed between Lewis recipient and Fisher donor rats. Recipients were injected with SFA, empty vehicle, or SFA in combination with a low dose of CsA intraperitoneally for two weeks, respectively. Controls received either low or high-dose CsA alone. Transplants were monitored for clinical signs of rejection. Serum levels of SFA and CsA were analyzed by mass spectrometry. Finally, histological evaluations for mononuclear infiltrates were performed on the day of rejection.

Results: : Intraperitoneal injection of SFA or CsA resulted in a dose dependent, stable serum level, respectively. No statistically significant effect was observed on graft survival by injecting empty vehicle or low-dose CsA. High dose CsA ameliorated median graft survival time significantly (p<0.01), however all transplants were rejected after treatment was stopped. SFA treatment resulted in long-term survival of more than 60% of corneal grafts (p<0.01). Infiltration of mononuclear cells was significantly reduced in animals receiving SFA compared to all other groups.

Conclusions: : Blockade of the priming process by affecting DC using SFA has a long term effect on graft survival in rat keratoplasty. Therefore, SFA seems a promising immunosuppressive drug to prevent the initiation of rejection episodes following keratoplasty.

Keywords: cornea: basic science • transplantation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×